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The EMCDDA exists to facilitate a more evidence-informed understanding of issues 
that are important for developing better drug-related policies and actions across 
Europe. In a new series of reports, we turn our attention to cannabis, a substance 
with a long history of use that has recently emerged as a controversial and 
challenging issue in both European and wider international drug policy debates.
Cannabis is the most commonly used illicit drug in Europe. It is also the drug about 
which both public attitudes and the political debate are most polarised. Interest in 
this area is rapidly growing, prompted by some quite dramatic international 
developments in the ways in which some countries and jurisdictions are now 
regulating this substance. For Europe, this means that questions on what constitutes 
an appropriate policy response to cannabis have become both topical and important.
In response, the EMCDDA is producing a set of papers that seek to explore, in an 
objective and neutral manner, some of the complex issues that exist in this area. We 
will be publishing a series of reports, each addressing a different aspect of this 
dynamic and complex policy area. Our aim in this series is to provide an overview of 
evidence and current practice for those with an interest in the area, to inform debate 
and not to advocate for any particular policy perspective.
In this report, we examine the evidence for, and practice of, making cannabis or 
cannabis-based medicines available for therapeutic purposes. This topic is of 
growing interest, not only because a number of European countries are developing 
policies in this area but also because the international framework may be changing 
following the recent review of cannabis by the WHO’s Expert Committee on Drug 
Dependence.
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5l Introduction
The medical use of preparations derived from the Cannabis sativa plant has a long history. 
However, by the twentieth century, medical use of cannabis had largely declined, and its 
consumption for medical purposes was already very limited when in 1961 cannabis was 
included in the United Nations Single Convention on Narcotic Drugs and classified as 
a drug that had no medical uses (see ‘A brief history of the medical use of cannabis and 
cannabinoids’, on page 7). In the past 20 years, however, there has been a resurgence of 
patient interest in using cannabis and cannabinoids to treat a variety of conditions, 
including chronic pain, cancer pain, depression, anxiety disorders, sleep disturbances and 
neurological disorders, the symptoms of which are reportedly improved by using cannabis 
(NASEM, 2017). 
Increased patient interest in the medical use of cannabis has been accompanied by 
renewed scientific interest in the medical use of substances found in the cannabis plant, 
namely cannabinoids. This followed the discovery, in the early 1990s, of a cannabinoid 
system in the human brain and body that was implicated in the control of important 
biological functions, such as cognition, memory, pain, sleep and immune functioning. 
However, the classification of cannabis as a drug without medical uses made it difficult to 
conduct clinical research (NASEM, 2017).
In the mid-1990s, citizens in several US states responded to patient demand for cannabis 
by passing referenda that legalised the medical use of cannabis for people with a variety of 
illnesses, such as chronic pain, terminal cancer and multiple sclerosis. A similar approach 
was later adopted in many other US states. In 1999, Canada introduced a medical 
cannabis programme that expanded over the subsequent decades in response to court 
decisions. In the early 2000s, Israel (2001) and the Netherlands (2003), and later other 
countries, such as Switzerland (2011), Czechia (2013), Australia (2016) and Germany 
(2017), legislated to allow the medical use of cannabis under specified conditions. Over 
a similar period, clinical trials have provided the basis for granting an authorisation for 
marketing in many EU Member States of a medicinal product, primarily based on cannabis 
extracts, that has proven effective in the treatment of muscle spasticity due to multiple 
sclerosis.
Most EU countries now allow, or are considering allowing, the medical use of cannabis or 
cannabinoids in some form. However, the approaches taken vary widely in terms of both 
the products allowed and the regulatory frameworks governing their provision. In this 
context, this report aims to provide a brief overview of current knowledge and the latest 
developments relating to medical use of cannabis and cannabinoids.
The report is intended to help a broad audience of interested readers, such as 
policymakers, practitioners, potential patients and the public, to understand the scientific, 
clinical and regulatory issues that arise when consideration is given to making cannabis or 
cannabinoids available to treat the symptoms of medical illnesses.
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Important caveats when interpreting this report’s findings
This report has been prepared to respond to growing policy interest in the issue of 
the use of cannabis and cannabinoids for medical purposes. Providing a short and 
clear overview of such a complex topic area is, however, challenging. Importantly, 
there are a number of caveats that need to be borne in mind when interpreting the 
findings of this report.
The area of medical use of cannabis and cannabinoids is extremely dynamic. The 
EMCDDA has endeavoured to ensure that this report is as accurate as possible at the 
time of writing. However, both the evidence base in this area and policies and 
practice are evolving rapidly.
There are a number of challenges involved in interpreting the available evidence on 
the effectiveness of cannabis medications. The review here is based on the evidence 
available at the time of writing. Until recently, medical interest in this topic was 
limited, a problem complicated by the large number of conditions for which 
cannabinoids are purported to be useful. This means that large, well-conducted 
studies are scarce. In addition, the knowledge base is constantly changing as new 
studies are conducted.
Reporting on developments in this area is also hampered by the lack of a common or 
agreed conceptual framework for describing the medical use of cannabis and 
cannabinoids. In this report, a simple typology is provided to help address this and 
aid the interpretation of the data. However, it is not always possible to apply this to 
the information sources on which the report is based.
National regulatory frameworks are also complicated and there may sometimes be 
a lack of clarity regarding both the details of the various approaches and how they 
operate in practice. In addition, they evolve over time, and experts sometimes 
disagree on how such frameworks should be interpreted legally.
l What topics does this report cover?
Part 1 of the report summarises the evidence on the medicinal properties of cannabis and 
cannabinoids from systematic reviews of randomised controlled clinical trials. It describes 
the strength of the evidence of medical benefits in various medical conditions, discusses 
the role that cannabinoid-containing medicines may play in treating these illnesses, and 
outlines what we know about the possible harms of short- and long-term medical use. 
A background paper accompanying this briefing provides more detail on the findings of 
recent systematic reviews of evidence from controlled trials on the effectiveness and 
safety of cannabis and cannabinoids (Hall, 2018).
Part 2 outlines the legal and regulatory frameworks that are relevant to allowing cannabis 
and cannabinoids to be used for medical purposes. This section describes the 
requirements placed on governments by the international drug control treaties. It also 
describes the type of evidence that pharmaceutical regulators usually require before 
approving medicines for clinical use in high-income countries. Finally, it considers whether 
cannabis could be regulated for medical use under special access schemes or as a herbal 
medicine.
Part 3 gives examples of the various ways in which selected countries have allowed the 
medical use of cannabis and cannabinoids.
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A brief history of the medical use of cannabis and cannabinoids
 ■ In the 19th century, cannabis tinctures were used in Britain and the US to relieve 
pain and nausea (Grinspoon and Bakalar, 1993; Mechoulam, 1986; Nahas, 1984).
 ■ The medical use of cannabis declined as drugs were developed in the early 20th 
century that could be given in standardised doses orally or by injection instead of 
cannabis extracts that varied in quality and content (Kalant, 2001; Pisanti and 
Bifulco, 2017).
 ■ The inclusion of cannabis in the Single Convention on Narcotic Drugs in 1961 as 
a drug with no medical uses ended its medical use in the countries that signed the 
treaty (Grinspoon and Bakalar, 1993).
 ■ A revival of interest in the medical uses of cannabis in the 1970s coincided with 
widespread recreational cannabis use among young people in the US (Institute of 
Medicine, 1999).
 ■ Governments feared sending the ‘wrong message’ to young people by allowing 
medical use, and the legal classification of cannabis made it difficult to investigate 
its medical uses in the US (Institute of Medicine, 1999).
 ■ Interest in potential medical uses was revived in the 1990s following the discovery 
of a cannabinoid system in the brain (Iversen, 2003; Pertwee, 1997), which 
suggested that cannabinoids could be used to treat chronic pain and neurological 
disorders such as multiple sclerosis and epilepsy (NASEM, 2017).
Part 4 summarises the regulatory issues that governments need to address when deciding 
to allow patients to use cannabis or cannabinoids for medical purposes. This includes 
making decisions about the types of cannabis products that patients are allowed to use, 
the medical conditions for which such products can be used, and the type of medical and 
regulatory supervision under which patients are allowed to use them.
l What do we mean by medical use of cannabis and cannabinoids?
The ‘medical use of cannabis and cannabinoids’ can refer to a wide variety of preparations 
and products (see Figure 1) that may contain different active ingredients and use different 
routes of administration. Although in practice some of the terms in this area have often 
been used rather loosely, the distinctions between them have both regulatory and medical 
implications, so it is important to define how we use them in this report.
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FIGURE 1
Cannabis and cannabinoids used for medical purposes — a broad typology
Examples of medicinal products and their active ingredients
Medicinal products
with marketing authorisation
Cannabis preparations
Cesamet and
Canemes
EpidiolexSativexMarinol and
Syndros
Containing 
nabilone
Containing 
dronabinol
Containing 
nabiximols
Containing 
cannabidiol
Synthetic cannabinoid 
similar to THC
Synthetic THC Plant-based; approx. 
equal quantities 
CBD/THC
Plant-based CBD
Raw cannabis Magistral preparations Standardised
cannabis preparations
Variable in THC/CBD composition
One important distinction between different forms of cannabis preparations and 
cannabinoids for medical use is between those that have a marketing authorisation for 
medical use and those that do not. Having a marketing authorisation means that an 
application for a medicinal product was submitted to a regulatory authority and, after 
evaluating the application, the regulatory authority granted authorisation. This usually 
implies that the product went through extensive clinical trials and that the drug has been 
tested for safety, effectiveness and side effects. Regulatory authorities also consider 
whether the product can be manufactured to a required level of quality.
In this report, we use ‘medicinal product’ to refer to the (plant-derived and synthetic) 
cannabinoid-containing products with a marketing authorisation. Outside the European 
Union, other terms, such as ‘product licence’, ‘drug approval’ or ‘registration certificate’, 
may be used to refer to a ‘marketing authorisation’.
The general term ‘cannabis preparations’ is used in this publication to refer to items 
derived from the Cannabis sativa plant that do not have a marketing authorisation for 
medical use. These may include the raw cannabis, such as the flowering tops, compressed 
resin or hash; oils extracted from the plant; concentrated cannabis extracts; and other 
cannabis preparations, such as soft gels, tinctures or edibles.
The raw cannabis may be transformed by a pharmacist into a magistral preparation for 
consumption in accordance with a specified medical prescription for an individual patient, 
or the raw cannabis may already have been transformed by the manufacturer (e.g. into 
capsules) in larger batches (standardised cannabis preparations). Examples of 
standardised cannabis preparations include preparations of cannabis flowers, such as 
Bedrocan; granulates, such as Bediol; and oil extracts, such as Tilray 10:10 Balance.
Cannabis preparations can vary greatly in composition, depending, for example, on the 
strain of cannabis, the growing conditions and how the preparations are stored. This 
means that they can be difficult to test for efficacy in clinical trials. In this report, the term 
‘medical use of cannabis’ denotes the use of cannabis preparations for medical purposes 
by smoking, vaporising or oral ingestion (see ‘Medical use of cannabis preparations  
— modes of consumption’, page 10).
Cannabinoids are substances found in the cannabis plant that act on specific receptors in 
the human brain and body (NASEM, 2017); they are the main active ingredients in both the 
medicinal products derived from cannabis and cannabis preparations. The two most 
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extensively studied are tetrahydrocannabinol (THC) and cannabidiol (CBD), but some of the 
other 102 cannabinoids and terpenoids in cannabis may also have medical uses (Russo 
and Marcu, 2017). Cannabinoids are also found in the human body (endocannabinoids), but 
those consumed for medical use may originate from the cannabis plant (plant-derived 
cannabinoids, also known as phytocannabinoids) or be synthesised in the laboratory 
(synthetic cannabinoids). Synthetic cannabinoids may bind to cannabinoid receptors and/
or produce similar effects to cannabinoids (Institute of Medicine, 1999; Iversen, 2007). 
Their chemical structure may not resemble that of any naturally occurring cannabinoids.
THC is the cannabinoid that produces the psychoactive effects sought by recreational 
users, such as euphoria, relaxation and heightened sensory experiences (NASEM, 2017). 
There is also evidence to support the medical use of THC in controlling nausea and 
vomiting, stimulating appetite and reducing pain (see below). CBD may moderate the 
psychoactive effects of THC, and it has medicinal properties, such as reducing epileptic 
seizures (NASEM, 2017).
Several cannabinoid-containing medicinal products have been authorised for marketing; 
the following are those most commonly referred to:
 ■ Marinol and Syndros (active ingredient — dronabinol) (1): oral capsules or an oral 
solution containing synthetic THC. Dronabinol is indicated for (1) anorexia associated 
with weight loss in patients with acquired immune deficiency syndrome (AIDS) and (2) 
nausea and vomiting associated with cancer chemotherapy, usually after previous 
treatments have failed.
 ■ Cesamet and Canemes (active ingredient — nabilone): oral capsules containing 
a synthetic cannabinoid similar to THC. The main indication for their use is nausea and 
vomiting associated with chemotherapy, usually after previous treatments have failed 
(Abuhasira et al., 2018).
 ■ Sativex (active ingredient — nabiximols): a medicinal product containing approximately 
equal quantities of THC and CBD from two cannabis extracts. This product, which is 
sprayed inside the cheek or under the tongue, has been authorised for the treatment of 
muscle spasticity resulting from multiple sclerosis (Iversen, 2007; Russo and Guy, 
2006).
 ■ Epidiolex (active ingredient — CBD): a plant-derived CBD oral solution indicated for the 
treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in 
patients 2 years of age or older.
In this publication, we focus on cannabis preparations and products of which medical use 
is allowed in at least one country.
In the past few years, cannabis-based items (e.g. herbs, hemp and oils) have been offered 
for open sale in shops in several EU countries, based on the claim that they have little or no 
psychoactive effect because they contain very low levels of THC and therefore are not 
controlled under national drug laws. They are sometimes referred to as ‘cannabis light’ 
products. Many of these, sometimes claiming to be high in CBD, are purported to be good 
for ‘health and well-being’. These fall outside the scope of the current publication, as they 
are not made available under any regulatory framework for medical use (see ‘Low-THC 
products and cannabis products associated with health and well-being’, page 20).
(1) Marinol and Syndros both contain synthetic delta-9-THC (dronabinol). However, ‘dronabinol’ may sometimes refer 
to plant-derived THC.
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Medical use of cannabis preparations — modes of consumption
An important issue in the provision of cannabis preparations for medical use is how 
they will be consumed.
The fastest route to intoxication, and the traditional mode of consumption for 
recreational users, is to roll the herbal cannabis or cannabis resin into a cigarette 
(often mixed with tobacco) and smoke it. As the smoke is absorbed through the lungs 
into the bloodstream, the effects of THC on the brain are felt in less than a minute.
The harms associated with smoking tobacco are well known. Although it appears 
from the limited evidence available that smoking cannabis may be somewhat less 
harmful, it may still damage the lungs. Accurate dosage is also difficult when 
cannabis is smoked. Safer and more precise methods of administration are available, 
such as vaporising below the point of combustion, infusing in hot water (‘tea’) or 
placing drops of oil in the mouth. Cannabis edibles, such as chocolates and baked 
goods, have become an important method of administration in the US. Digesting 
cannabis from edibles, infusion or capsules results in delayed effects — the effects 
of THC are felt only after 30-60 minutes — but more accurate pharmaceutical dosing 
is possible.
In the European Union, no country that permits medical use of cannabis preparations 
recommends smoking as a mode of consumption.
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Part 1
What evidence is there that cannabis 
and cannabinoids have medical uses?
l How do we assess the effectiveness of medicinal products?
In most high-income countries, regulatory authorities grant 
a marketing authorisation after an extensive evaluation of 
a submitted application for a new medicinal product. 
Having a marketing authorisation usually implies that the 
product went through extensive clinical trials (2) and that 
the drug has been tested for safety, effectiveness and side 
effects (Osakwe, 2016; Rago and Santoso, 2008).
In controlled clinical studies, patients are randomly 
assigned to receive the drug, a placebo, no treatment or 
another active treatment for their condition. These trials 
generally need to show that the drug is more effective than 
placebo, or another currently used medicine, in relieving 
the symptoms of the condition (Osakwe, 2016; Rago and 
Santoso, 2008). There also needs to be evidence that any 
harms that the medicine causes are outweighed by the 
benefits of taking it. On the basis of all the evidence, the 
regulatory authority may grant a marketing authorisation 
for the medicinal product. The need to take account of 
both efficacy and potential harms means that in some 
cases authorisation is given when the new medicine is as 
effective as or slightly less effective than currently used 
medicines but has a better safety profile.
Following authorisation, for some medicinal products, 
clinical guidelines may be drafted to supplement the 
product information provided by the manufacturer. In this 
case, an organisation such as the National Institute for 
Health and Care Excellence in the United Kingdom, and 
specialist national and international medical colleges and 
societies, convene expert groups of clinicians to develop 
such guidelines to advise medical practitioners and 
patients on how the medicine may be used in clinical 
practice (Shekelle et al., 2012). The product information 
and any clinical guidelines summarise the evidence on its 
safety and efficacy. They provide information on such 
things as dosage forms and dose ranges, adverse effects, 
(2) Not all medicinal products with a marketing authorisation have 
undergone extensive clinical trials; examples are generic drugs and 
traditional or well-established medicines. 
clinical conditions in which the drug may be 
contraindicated, and interactions with other commonly 
used medicines. Clinical guidelines also usually contain 
advice on where a new medicine fits within established 
forms of treatment for a condition (e.g. as a first-line 
treatment or as an adjunctive treatment).
In many countries, and in the European Union, after 
a medicinal product receives a marketing authorisation, 
the health authorities are obliged to monitor adverse 
events among patients who use it. This post-market 
surveillance aims to detect rare and serious adverse 
events that may not have been detected during the clinical 
trials that led to the authorisation. Clinical trials are usually 
short term and are often conducted in highly selected 
groups of patients. Rarer adverse events may come to light 
only when a drug has been used to treat a large number of 
unselected patients (Osakwe, 2016; Rago and Santoso, 
2008).
l What is the current evidence on the effectiveness of cannabis and cannabinoids as medicines?
This section summarises the evidence on the medicinal 
properties of cannabis and cannabinoids from systematic 
reviews of randomised controlled clinical trials. As noted 
above, the evidence base is evolving rapidly but is currently 
quite limited and fragmented, which needs to be borne in 
mind when considering any evidence review. A particular 
challenge in interpreting the evidence is that often 
different cannabis products and preparations have been 
used, which may have contained quite different active 
ingredients. For ease of reading, the term ‘cannabinoids’ 
has been used in this section when multiple substances 
were under study. Additional details on the specific 
cannabinoids involved can be found in the background 
paper accompanying this report (Hall, 2018).
The evidence from controlled clinical trials that is 
summarised below (and in Table 1, page 14) suggests that 
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cannabinoids relieve the symptoms of some illnesses. In 
these cases, cannabinoids are often used as adjunctive 
treatments, meaning that they are added to other medical 
treatments rather than used on their own. They are also 
typically used only after a patient has failed to respond to 
recommended treatments for these conditions.
l As anti-emetics
Controlled clinical trials have compared the anti-emetic 
effects of THC (taken orally) with those of either a placebo 
or another anti-emetic drug in patients with nausea and 
vomiting related to cancer chemotherapy. Systematic 
reviews of the trials (e.g. NASEM, 2017; Smith et al., 2015; 
Tramer et al., 2001; Whiting et al., 2015) have concluded 
that THC and other cannabinoids that produce similar 
effects (known as cannabinoid agonists) were more 
effective than placebo and often had levels of 
effectiveness similar to those of the anti-emetic drugs with 
which they were compared.
The most recent comprehensive reviews differed in their 
evaluations of the strength of the evidence for the efficacy 
of cannabinoids as anti-emetics. Whiting et al. (2015) 
rated the quality of these trials as ‘low’ because the 
majority of authors failed to include patients who 
discontinued treatment in their analyses of outcomes. 
A Cochrane review (Smith et al., 2015) also concluded that 
the evidence was weak because of limitations in the study 
designs and the use of outdated comparison treatments. 
However, the US National Academies of Sciences, 
Engineering, and Medicine (NASEM) found that there was 
‘conclusive evidence’ that oral cannabinoids were effective 
in treating chemotherapy-induced nausea and vomiting 
(NASEM, 2017).
These clinical trials have major limitations, as noted in all 
reviews. First, newer cancer chemotherapy regimens 
produce less nausea and vomiting than the treatments 
used in trials conducted between 1975 and 1991 (Smith et 
al., 2015). Second, the active treatment with which THC 
and other cannabinoids were most often compared was 
prochlorperazine, and newer anti-emetic drugs provide 
much better control of nausea and vomiting than 
prochlorperazine (Institute of Medicine, 1999; Navari, 
2009). There have been very few clinical trials comparing 
the anti-emetic effects of cannabinoids with those of these 
newer agents in cancer patients treated with current 
chemotherapy regimens (NASEM, 2017; Navari, 2009). 
Such trials are required to clarify the role of cannabinoids 
in managing nausea and vomiting in cancer patients. There 
is very limited evidence on the role of cannabinoids in 
treating nausea and vomiting caused by other medical 
conditions (NASEM, 2017).
l For stimulating appetite
Marinol was approved in the United States in 1999 for use 
as an appetite stimulant in patients with AIDS-related 
wasting. This approval was based on very few small clinical 
trials (Beal et al., 1995; Lutge et al., 2013; Tramer et al., 
2001). Systematic reviews concluded that these trials 
provided weak evidence for the use of THC as an appetite 
stimulant because there was substantial risk of bias (Lutge 
et al., 2013; NASEM, 2017; Whiting et al., 2015). There is 
now much less need to stimulate appetite in AIDS patients 
because very few people infected with human 
immunodeficiency virus (HIV) develop AIDS-related 
wasting if they are treated with highly active antiretroviral 
drugs (NASEM, 2017). There is insufficient evidence to 
assess the value of dronabinol in stimulating appetite in 
people with other disorders, such as anorexia nervosa and 
cancer cachexia (NASEM, 2017).
l For neuropathic pain and spasticity in multiple sclerosis
Clinical trials have evaluated the efficacy of cannabinoids 
in treating muscle spasm and neuropathic pain in patients 
with the neurodegenerative disorder multiple sclerosis. 
The product most often trialled has been nabiximols 
(Sativex), a standardised cannabis extract with 
approximately equal quantities of THC and CBD delivered 
as an oromucosal spray.
In randomised clinical trials, some patients who received 
nabiximols (in addition to their existing treatment) 
reported less muscle spasticity than patients who were 
given a placebo (Collin et al., 2010; Novotna et al., 2011; 
Wade et al., 2004). Clinician ratings of the patients’ muscle 
spasticity, however, showed only marginal reductions (e.g. 
Koppel et al., 2014; NASEM, 2017; Whiting et al., 2015; 
Zajicek et al., 2003). Whiting et al. described the evidence 
for efficacy as ‘moderate’ in quality. The NASEM review 
concluded that cannabinoids were ‘probably effective’ in 
reducing patient-reported muscle spasticity but described 
their clinical effects as ‘modest’.
l For chronic non-cancer pain
One of the most commonly reported reasons patients use 
cannabis for medical purposes in the United States is to 
treat chronic pain that is not caused by cancer (chronic 
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non-cancer pain, CNCP) (NASEM, 2017). This includes 
neuropathic pain, arthritis, back pain, neck and shoulder 
pain, and headaches.
Andreae et al. (2015) reported a Bayesian meta-analysis of 
data from 178 patients with various types of neuropathic 
pain in five randomised controlled trials (RCTs) of inhaled, 
vaporised herbal cannabis. The patients were assessed for 
up to 2 weeks. The authors found that patients vaporising 
herbal cannabis were three times more likely (odds ratio 
(OR) = 3.2) to report a 30 % reduction in pain than those 
given a placebo.
A Cochrane review assessed studies that compared the 
efficacy of cannabinoids (herbal, plant-based, synthetic) 
with that of placebo for reducing chronic neuropathic pain 
in adults (Mucke et al., 2018a). It included 16 studies with 
1 750 participants who received a cannabinoid medicine 
(nabiximols or THC and its analogues) or a placebo for 
2-26 weeks. The authors rated the study quality as low in 2 
studies, moderate in 12 studies and high in 2 studies. They 
found that cannabinoids increased the percentage of 
patients who achieved a 50 % reduction in pain compared 
with placebo from 17 % to 21 %. The number who needed 
to be treated to benefit was 20. The percentage who 
achieved a 30 % reduction in pain was 39 % compared 
with 33 % and the number who needed to be treated to 
benefit was 11. There were more withdrawals from 
treatment because of adverse events in the cannabinoid 
condition than in the placebo condition (10 % vs. 5 %).
Stockings et al. (2018a) reported a comprehensive review 
of controlled clinical trials and observational studies 
comparing cannabinoids and placebo for treating various 
types of CNCP. They included 91 publications that involved 
9 958 participants in 47 RCTs (24 parallel group studies 
and 23 crossover trials) and 57 observational studies. 
Forty-eight studies included patients with neuropathic 
pain (16 in patients with multiple sclerosis and 32 in 
patients with neuropathic pain from other conditions). They 
also included 7 studies of patients with fibromyalgia, 1 
study of patients with rheumatoid arthritis and 48 studies 
of patients with other types of CNCP (13 in patients with 
multiple sclerosis-related pain, 6 in patients with visceral 
pain and 29 in samples of patients with mixed or 
undefined CNCP). The percentage of CNCP patients who 
achieved a 30 % reduction in pain intensity, when averaged 
across RCTs, was 29 % for patients treated with 
cannabinoids, compared with 26 % for those who received 
a placebo. This difference was statistically significant. 
However, a higher proportion of patients treated with 
cannabinoids reported adverse events. Stockings et al. 
concluded that the evidence for the effectiveness of 
cannabinoids in treating CNCP was limited. There was 
limited evidence of benefit in other pain-related domains, 
such as sleep.
l For palliative cancer care
Media discussions of the potential medical uses of 
cannabis often mention palliative care for patients with 
terminal cancer. Medical use of cannabis and 
cannabinoids has been advocated for managing a broad 
range of symptoms reported by terminally ill cancer 
patients, by controlling pain, stimulating appetite, reducing 
anxiety and improving sleep.
Mucke et al. (2018b) conducted a systematic review and 
meta-analysis of the efficacy, tolerability and safety of 
cannabinoids in palliative medicine. They found nine 
studies with 1 561 participants, all of which were judged to 
be at moderate risk of bias. They did not find any significant 
differences between cannabinoids and placebo in 
improving calorie intake, appetite, nausea or vomiting, 
pain, or sleep in terminally ill cancer patients. They also 
found no high-quality evidence that cannabinoids were of 
value for treating anorexia or cachexia in cancer patients. 
The strength of these conclusions was limited by the small 
number of high-quality studies and their small sample 
sizes, which reduced the chance of finding any differences 
in favour of cannabinoids. Larger, better-designed trials are 
needed to assess the value of cannabis and cannabinoids 
in palliative cancer care.
l For intractable childhood epilepsy
Parents of children with intractable epilepsy have reported 
that oils rich in CBD reduce the frequency and severity of 
their children’s seizures (Devinsky et al., 2016; Hussain et 
al., 2015; Press et al., 2015). These parental reports have 
been supported by a large, open-label trial and a large, 
multisite RCT (Devinsky et al., 2016; Devinsky et al., 2017; 
Dos Santos et al., 2014; Friedman and Devinsky, 2015). 
Early systematic reviews (e.g. Gloss and Vickrey, 2014) 
concluded that no reliable conclusions could be drawn 
about the efficacy and safety of CBD. A systematic review 
of clinical trials conducted since then (Stockings et al., 
2018b) found that adding CBD to conventional anti-
epileptic drugs significantly reduced seizure frequency in 
children with Dravet syndrome or Lennox-Gastaut 
syndrome. The review concluded that more controlled 
clinical trials were needed to specify the doses of CBD that 
reliably produce anti-epileptic effects with a minimum of 
adverse events and minimal interaction with other anti-
epileptic medications, such as benzodiazepines. Clinical 
pharmacological studies are needed to better define drug 
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doses and interactions with other anti-epileptic 
medications. Clinical trials may then be required to assess 
whether CBD is useful in treating other types of intractable 
epilepsy in children and adults (Stockings et al., 2018b).
l Other medical uses of cannabinoids
Patient groups and some doctors have advocated using 
cannabis and cannabinoids to treat a variety of conditions 
in addition to those described so far. These conditions 
include anxiety disorders, such as post-traumatic stress 
disorder; depressive disorders; sleep disorders; types of 
chronic pain not included in the clinical trials to date; 
degenerative neurological conditions; and inflammatory 
bowel diseases such as Crohn’s disease. Some patients 
with these conditions have reported clinical benefits from 
using cannabis or cannabinoids.
For the great majority of these medical conditions, there is 
either no evidence of effectiveness from controlled clinical 
trials or limited evidence from studies that are rated as 
susceptible to bias because they used small patient 
samples, were poorly controlled or did not compare 
cannabis or cannabinoids with placebo or active drug 
treatments (NASEM, 2017; Whiting et al., 2015). Medical 
professionals who treat these conditions may be reluctant 
to use cannabinoids outside clinical trials in the absence of 
such evidence (e.g. Martin et al., 2018). Patients 
nonetheless use cannabis and cannabinoids to treat these 
symptoms in countries where they are able to do so. This 
highlights the need to expand the evidence base by 
undertaking robust studies that cover the full range of 
cannabis preparations being used, including addressing 
the issue raised by some patients who report greater 
benefit from using the whole plant than from using single 
extracts of cannabinoids, the so-called entourage effect 
(Russo, 2011).
l Summary
Table 1 provides an overview of the current evidence for 
the medical use of cannabis and cannabinoids as well as 
highlighting the limitations of and important gaps in the 
evidence. This emphasises the need for additional 
research and clinical studies, including larger and better-
designed trials, studies looking at dosage and interactions 
between medicines, and studies with longer-term follow-
up of participants.
TABLE 1
Summary of the evidence for the medical use of cannabis and cannabinoids
Disease/symptoms Products tested Strength of 
evidence
Limitations
Nausea and vomiting associated with 
cancer chemotherapy
Cannabinoids Weak Few studies testing against newer, more effective 
anti-emetics.
Newer chemotherapy regimens produce less nausea.
Little evidence available about use in other types of 
nausea.
Appetite stimulant in patients with 
AIDS-related wasting
Dronabinol/THC Weak Fewer AIDS-related cases available to treat now.
Little evidence available about use to stimulate 
appetite in people with other conditions.
Muscle spasm in patients with multiple 
sclerosis
Nabiximols Moderate Patients report reductions, but more limited impact 
on clinician ratings.
CNCP, including neuropathic pain Cannabis and 
cannabinoids
Moderate Small (but statistically significant) effect compared 
with placebo.
Palliative care for cancer Cannabinoids Insufficient Larger, better-designed trials are needed.
Intractable childhood epilepsy CBD Moderate Evidence for use in adjunctive therapy in people with 
Dravet or Lennox-Gastaut syndrome.
More studies are needed to look at dosage, 
interactions and use in people with other forms of 
epilepsy.
Other medical uses, such as sleep 
disorders, anxiety disorders, depression, 
degenerative neurological disorders, and 
inflammatory bowel disease
Cannabis or 
cannabinoids
Insufficient Some evidence for short-term effects in some 
conditions (e.g. sleep disorders) but larger, better-
designed trials are needed, with longer follow-up.
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l What health risks are associated with the medical use of cannabis and cannabinoids?
l What are the short-term risks?
The short-term adverse effects of medical cannabinoids 
and cannabis have been evaluated in the randomised 
controlled clinical trials summarised above. Follow-up in 
trials of THC for nausea and vomiting ranged from 1 to 6 
days, and in trials of cannabinoids to stimulate appetite 
and reduce pain and muscle spasticity it ranged from 8 to 
15 weeks (Whiting et al., 2015). In general, the short-term 
adverse events reported were similar to those of other 
commonly used medicines and related to symptoms such 
as dizziness, dry mouth, disorientation, nausea, euphoria, 
confusion and somnolence. Serious adverse events were 
rare.
A 1999 review by the Institute of Medicine, US National 
Academies of Science (now the Health and Medicine 
Division, NASEM) concluded that the short-term adverse 
effects of cannabinoids were similar to those of other 
commonly used medicines (Institute of Medicine, 1999). 
Wang et al.’s (2008) review of these trials did not find an 
increased risk of serious adverse events in patients using 
cannabinoid drugs (whether plant extracts or THC 
preparations) compared with placebo. They cautioned, 
however, that many of these trials had a limited ability to 
detect rare but serious adverse events because of their 
small sample sizes and their failure to follow up patients 
who discontinued.
Whiting et al. (2015) conducted a meta-analysis of 
short-term adverse events in 79 randomised trials that 
evaluated the effectiveness of cannabinoids in treating 
nausea and vomiting, chronic pain, spasticity due to 
multiple sclerosis, depression, anxiety, sleep disorders, 
psychosis, glaucoma and movement disorders, and in 
stimulating appetite. The incidence of these adverse 
events did not differ between cannabinoids. Patients 
receiving cannabinoids were more likely than those 
receiving a placebo to report an adverse event (OR = 3.03) 
and slightly more likely to report a serious adverse event 
(OR = 1.41). Patients receiving cannabinoids were also 
more likely than those receiving a placebo to withdraw 
from a study because of adverse events (OR = 2.94). The 
adverse events most commonly reported by patients 
receiving cannabinoids were dizziness, dry mouth, 
disorientation, nausea, euphoria, confusion and 
somnolence. Serious adverse events were much rarer. 
They included confusion, hallucinations, paranoia and 
symptoms of psychosis.
l What are the long-term risks?
There is less evidence about the risks of long-term medical 
use of cannabinoids, but in general those reported are 
similar to those reported for short-term use. Over time, 
more people report adverse events, but these are generally 
mild to moderate. More research is needed, however, 
including on the long-term use of CBD to treat intractable 
childhood epilepsy.
There is some research on adverse events reported by 
people using cannabinoids daily for months or years to 
treat chronic pain or muscle spasticity related to multiple 
sclerosis (Wang et al., 2008). Serpell et al. (2013) reported 
the longest follow-up of adverse events in multiple 
sclerosis patients treated with nabiximols for spasticity. 
They assessed adverse events in patients who participated 
in a 6-week RCT of nabiximols and who then received the 
drug in an open-label phase for up to 3 years. Eighty-four 
percent (n = 145) continued in the open-label trial; 35 used 
nabiximols for up to 1 year, 43 used them for up to 2 years, 
and 4 used them for up to 3 years. Ninety-five percent of 
patients experienced an adverse event during the follow-
up, but the majority were mild to moderate. The most 
common were dizziness, fatigue and headache. Twenty-
three patients (16 %) withdrew from the study because of 
adverse events.
Two observational studies have reported on adverse 
effects in cancer patients (Bar-Lev Schleider et al., 2018) 
and elderly patients (Abuhasira et al., 2018) treated in 
a leading Israeli cancer hospital between January 2015 
and October 2017. Adverse events were assessed in 
a telephone interview conducted 6 months after treatment 
started. Among cancer patients, 31 % reported an adverse 
event; these most commonly related to dizziness (8.0 %), 
dry mouth (7.3 %), increased appetite (3.6 %), sleepiness 
(3.3 %) and psychoactive effects (2.8 %) (Bar-Lev 
Schleider et al., 2018). The prevalence and type of adverse 
events were very similar in older patients treated with 
cannabis for more varied medical conditions (Abuhasira et 
al., 2018).
There have not yet been any studies of adverse events 
associated with the regular use of CBD in children treated 
for intractable epilepsy. This should be a research priority 
given concerns about the possible effects of long-term 
medication use on brain development in children and 
adolescents.
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l What can be learned about potential risks from studies of long-term recreational cannabis use?
Some of the harms reported among long-term users of 
recreational cannabis could possibly occur among 
long-term medical users of cannabis or cannabinoids. 
These include the development of dependence as well as 
a range of possible physical and mental health problems. 
A brief summary of the risks of long-term recreational 
cannabis use is given in this section; details are available in 
the background paper (Hall, 2018).
Cannabis dependence
Cannabis dependence or cannabis use disorders are 
potential consequences of long-term use (Hall, 2015). 
These disorders are characterised by a difficulty in 
controlling use or an inability to stop using when an 
individual wishes to do so. As a result, that person may 
continue to use cannabis despite its harming their health 
or well-being or impairing their performance of social roles.
Cannabis dependence has been studied primarily in 
recreational cannabis users who typically begin in 
adolescence and smoke potent cannabis products daily 
over months and years. In the early 1990s, recreational 
cannabis users’ lifetime risk of developing dependence 
was estimated to be 9 % in the United States (Anthony, 
2006), compared with 32 % for nicotine, 23 % for heroin, 
17 % for cocaine, 15 % for alcohol and 11 % for stimulants 
(Anthony et al., 1994; Hall et al., 1999).
Other risks
Epidemiological studies of recreational cannabis users 
have examined the effects of sustained, daily recreational 
cannabis use in adolescence and early adulthood on 
psychosocial outcomes in young adulthood (Hall et al., 
2016; NASEM, 2017). There has been only a small number 
of well-controlled studies of adverse health effects, such 
as cancers and heart diseases, among long-term cannabis 
smokers (Aldington et al., 2008; Hall et al., 2016; Hashibe 
et al., 2006; NASEM, 2017). These indicate that long-term 
cannabis smoking is associated with an increased risk of 
chronic bronchitis (Hall et al., 2016; NASEM, 2017). 
Long-term recreational cannabis use has also been 
associated with impaired memory, attention, decision-
making and planning (Crean et al., 2011; Solowij et al., 
2002), as well as with psychological disorders (Hall et al., 
2016; NASEM, 2017), although there are few prospective 
studies of these disorders (Hall et al., 2016; NASEM, 2017).
Recent reviews of the epidemiological evidence on 
cardiovascular outcomes suggest that cannabis smoking 
may trigger myocardial infarction (Franz and Frishman, 
2016; Hall et al., 2016; NASEM, 2017) and stroke in 
younger recreational users (Hall et al., 2016). It is uncertain 
whether cannabis smoking increases the risks of cancers. 
There have been inconsistent findings in epidemiological 
studies: some have failed to find an increased cancer risk; 
a few case-control studies have found a modest elevation 
of risk in very heavy long-term cannabis smokers 
(Aldington et al., 2008; Hall et al., 2016; Hashibe et al., 
2006).
It can be difficult to estimate the extent to which the risks 
associated with long-term recreational cannabis use would 
apply to long-term, medically supervised cannabis use. In 
general, there is an absence of studies, and the risks are 
influenced by a number of factors, such as the type of 
product and mode of consumption, which may be different 
when cannabis or cannabinoids are used for medical 
purposes. For example, if a patient consumes 
cannabinoids in a capsule or dissolved in oil, the 
respiratory risks associated with cannabis smoking would 
be avoided. Similarly, the use of vaporisers would also 
reduce the risk, but to what extent is not clear.
l Summary
The short-term health risks associated with the medical 
use of cannabis and cannabinoids, as reported in trials, 
were similar to those of other commonly used medicines 
and related to symptoms such as dizziness, dry mouth, 
disorientation, nausea, euphoria, confusion and 
somnolence. Serious adverse events were rare. There is 
less evidence about the health risks of long-term medical 
use of cannabinoids, but in general those reported are 
similar to those reported for short-term use. Some of the 
harms reported among long-term users of recreational 
cannabis could possibly apply to the long-term medical 
use of cannabis and cannabinoids, but more research is 
needed to draw evidence-based conclusions.
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Part 2
What regulatory frameworks are 
relevant to the medical use of cannabis 
and cannabinoids?
This section outlines the requirements for medical use of 
cannabis and cannabinoids under the international drug 
control treaties and the approaches that are generally used 
to evaluate and approve medicines in European and other 
high-income countries. It describes schemes that are 
designed to allow seriously ill patients to use unauthorised 
medicines in certain circumstances. It also briefly 
describes approaches to the regulation of herbal 
medicines.
l Is medical use of cannabis and cannabinoids allowed under the international drug control treaties?
Under the international drug control treaties, the use of 
cannabis is limited to scientific and medical purposes 
(UNODC, 2013). The treaties impose requirements on 
signatory countries that permit the medical use of 
cannabis and other drugs that are under international 
control (INCB, 2017). The treaties require tighter regulation 
of cannabis than medicines that are not under 
international control. For example, they require that 
governments establish a national agency that controls 
cannabis production and supply for medical use. This 
agency has to report to the International Narcotics Control 
Board (INCB) on the quantities of cannabis that are used 
for medical purposes and on the number of patients who 
are treated using cannabis-based medicines.
The treaties also require that the medical use of cannabis 
and cannabinoids be supervised by medical practitioners 
and that these drugs be dispensed by prescription. The 
drugs should be used only if there is evidence of their 
quality, safety and efficacy for medical use. At national 
level, the medical use of cannabis and other controlled 
drugs may involve monitoring the behaviour of prescribers 
and patients to ensure that cannabis-based medicines are 
appropriately prescribed and that they are not diverted to 
non-medical use or abused by patients.
In a recent development, the World Health Organization 
Expert Committee on Drug Dependence (WHO-ECDD) 
dedicated a special session to cannabis and undertook 
a critical review of CBD (June 2018). The WHO-ECDD 
recommended that preparations considered to be pure 
CBD should not be placed under international drug control 
because the substance does not have psychoactive 
properties, and no case reports of abuse or dependence 
have been reported. In addition, the WHO-ECDD 
undertook a critical review of cannabis and cannabis-
related substances in November 2018 (3). The decision on 
whether or not to adopt the recommendations will be 
subject to a vote by the UN Commission on Narcotic Drugs, 
which next meets in March 2019 (WHO, 2018).
l What are the regulatory frameworks within which cannabis or cannabinoids are authorised for medical use at European level?
Medicines regulation in Europe is based on a network of 
50 medicines regulatory authorities in 31 European 
Economic Area (EEA) countries (comprising the 28 EU 
Member States, Iceland, Liechtenstein and Norway). This 
system ensures that there is consistent regulation of 
pharmaceuticals across the European Union in order to 
protect public health and ensure that EU citizens have 
access to high-quality, safe and effective medicines 
(EMA, 2016).
Medicines can be authorised in the European Union by one 
of three routes. The first is a centralised procedure under 
the responsibility of the European Medicines Agency 
(EMA) that allows a single EU-wide authorisation for 
marketing of a pharmaceutical drug. The use of the 
centralised authorisation procedure is compulsory for 
(3) For WHO-ECDD recommendations see the WHO website: https://www.
who.int/medicines/access/controlled-substances/ecdd_41_meeting/en/ 
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most innovative medicines, including biotechnology-
derived medicinal products, advanced therapy medicinal 
products, medicines with a new active substance 
indicated for major therapeutic areas (AIDS, cancer, 
neurodegenerative disorders, diabetes, autoimmune 
diseases and other immune dysfunctions, and viral 
diseases) and medicines for rare diseases (orphan 
medicinal products).
The second is a decentralised procedure in which 
companies can apply for simultaneous authorisation of 
a medicine in more than one EU Member State. This 
applies if the medicine has not yet been authorised in any 
EU country and does not fall within the scope of the 
centralised procedure.
The third is a mutual recognition route in which companies 
that have a medicine authorised in one EU Member State 
can apply for this authorisation to be recognised by other 
EU countries. All regulatory processes require companies 
to present evidence of a medicine’s quality, efficacy and 
safety, based mostly on evidence from controlled clinical 
trials for the medical condition for which authorisation is 
sought (EMA, 2016).
The EMA is responsible for the scientific assessment of 
new medicines submitted through the centralised 
procedure, and the European Commission grants an 
EU-wide marketing authorisation to medicines for which 
the benefit-to-risk ratio is positive on the basis of these 
evaluations. Decisions on pricing and reimbursement are 
made by Member States in the light of the role that the 
medicine may play in each of their health systems. The 
EMA, through the pharmacovigilance system, also 
conducts routine monitoring of the safety of centrally and 
nationally authorised medicines, imposes risk 
management measures and maintains a database on 
suspected adverse drug reactions.
To date, except for Acomplia, an inverse agonist at the CB
1
 
receptor, which was withdrawn from the market in 2008, 
no EU-wide marketing authorisation has been granted for 
cannabinoid-containing medicinal products. However, 
nabiximols has received approval in several countries 
using the decentralised and mutual recognition 
procedures. A marketing authorisation application is 
currently under review at the EMA for a product the active 
substance of which is CBD. This product is intended to be 
used in adjunctive therapy for seizures associated with 
Lennox-Gastaut syndrome or Dravet syndrome.
l What regulatory frameworks are used to authorise cannabis or cannabinoids for medical use at national level?
National regulatory authorities license the use of 
a medicinal product based on the European requirements 
for marketing authorisations, that is, when there is good 
evidence that it can be manufactured to a required level of 
quality and there is evidence from clinical trials that it is 
safe and effective when used to treat patients with 
specified medical disorders (Osakwe, 2016; Rago and 
Santoso, 2008). Evidence of quality is ensured by 
a specific chemical or biological evaluation and requires 
the use of standards of good manufacture. Evidence of 
safety and efficacy requires preclinical pharmacological 
and toxicological research as well as clinical trials. It is 
confirmed usually by randomised controlled clinical trials 
that compare the effects of the medicinal product with 
those of a placebo, or an active treatment, in patients with 
the specified medical condition.
After a medicine has been licensed by national authorities, 
its safety is monitored through the national 
pharmacovigilance system, or at European level when it 
has been authorised in more than one Member State. This 
monitoring allows the detection of rare and sometimes 
unexpected serious adverse events that may not have 
been detected in the relatively short time frame of the 
clinical trials (conducted in selected patient populations) 
conducted to obtain authorisation for medical use.
l What other regulatory approaches are used to make cannabis or cannabinoids available for medical use without formal marketing authorisation?
Many pharmaceutical regulatory systems include schemes 
that allow patients to access unapproved medicines under 
medical supervision. These schemes are usually used by 
patients who have serious illnesses, such as terminal 
cancer or degenerative neurological diseases, that have 
not responded to conventional treatments. They often 
provide early access to medicines that are undergoing 
clinical trials or that have been approved for use in other 
countries (Martinalbo et al., 2016).
Under these schemes, access to unapproved medicines 
usually requires a prescription by a licensed medical 
practitioner and approval by the pharmaceutical regulator 
for the patient to obtain and use the medicine. Patients 
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often pay the costs of obtaining it; sometimes the 
pharmaceutical company provides it at no cost to the 
patient on compassionate grounds. The prescriber may be 
required to report patient outcomes and any adverse 
events. A minority of patients in developed countries use 
this method to access unapproved medicines, usually to 
treat serious illnesses that have not responded to the 
standard treatments.
Many EU Member States have some type of 
compassionate access programme for unauthorised 
pharmaceuticals (Balasubramanian et al., 2016). These are 
known by various names depending on the country, such 
as early-access programmes, special access programmes, 
named patient programmes and managed access 
programmes. Regardless, all these programmes make 
a medicine available to a patient before its authorisation 
and commercial launch in the country (Balasubramanian 
et al., 2016).
In Europe, access to cannabis preparations, including 
magistral preparations, where allowed, appears to be 
provided primarily through compassionate or exceptional 
use programmes (HPRA, 2017). In countries where access 
to cannabis preparations is given in this way, it is usually 
granted for the treatment of a narrow range of medical 
conditions. One common feature of these access 
programmes is a specialised prescriber who has a specific 
licence to prescribe non-authorised cannabis preparations 
(HPRA, 2017; Krcevski-Skvarc et al., 2018). Other 
European countries allow access to cannabis preparations 
through expanded access programmes. These 
programmes use country-specific regulatory tools that 
allow patients with unmet medical needs access to 
a medicine in clinical development before its official launch 
(HPRA, 2017; Krcevski-Skvarc et al., 2018).
There is wide variation in how these programmes are 
implemented at national level, and each country has its 
own rules and procedures for allowing cannabis 
preparations to be provided to patients.
l Could cannabis be sold as a herbal medicine?
Most pharmaceutical regulatory systems allow the use of 
herbal medicines that do not meet the same requirements 
as those for pharmaceutical medicines (Ekor, 2014; WHO, 
2015). For example, manufacturers of traditional herbal 
medicines with well-established uses are not usually 
required to provide evidence of efficacy and safety from 
clinical trials. Instead, they are required only to show 
evidence of product quality and consistency to ensure that 
consumers receive standardised doses of herbal products 
that are free from contaminants and adulterants. These 
herbal medicines are distinct from health foods and similar 
products, which are outside the scope of this report (see 
‘Low-THC products and cannabis products associated 
with health and well-being’, page 20).
The justification for this minimal regulatory approach is 
that herbal medicines have histories of traditional or 
well-established use, generally in the absence of reports of 
serious adverse events. Critics of herbal medicines point 
out that there is a lack of evidence to support many of the 
therapeutic claims made for these traditional herbal 
medicines. Moreover, many herbal medicines are used in 
addition to (rather than instead of) conventional medicines 
and may interact with pharmaceutical medicines in 
sometimes unknown ways that may harm patients (Ekor, 
2014; Sammons et al., 2016).
The preference among some patients for the medical use 
of herbal preparations of the whole cannabis plant rather 
than pharmaceutical products has strong similarities to 
the reasons people give for using traditional herbal 
medicines. Herbal cannabis is sometimes preferred 
because of the hypothesised entourage effect, meaning 
that the combination of cannabinoids and other 
substances in the whole plant has a greater medical effect 
than single cannabinoids extracted from it (Russo, 2011).
Under the European Union’s medicinal products directive 
(European Parliament and Council, 2001), drugs under 
international control must be distributed on prescription, 
whereas herbal medicines, with a simplified registration 
procedure (based on traditional use), are usually non-
prescription. On this basis, cannabis would be difficult to 
regulate as a traditional herbal medicine in the European 
Union while it remains a drug under international control or 
while the national legislation in many countries classifies 
cannabis as a drug that has no medical uses. Major 
challenges in regulating cannabis products as herbal 
medicines would remain even if these obstacles were 
removed. These would include characterising and 
standardising the cannabinoid and other chemical 
constituents of herbal cannabis (Martin and Bonomo, 
2016), assessing their stability in stored medicines (Martin 
and Bonomo, 2016), and ensuring that herbal cannabis 
products were free of contamination by microbes (e.g. 
fungi and moulds), heavy metals and pesticides (Dryburgh 
et al., 2018).
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Low-THC products and cannabis products 
associated with health and well-being
This publication focuses on the regulation of 
cannabis preparations and cannabinoid products for 
medical use. However, in the past few years a range 
of items derived from cannabis (herbs, hemp, oils) 
have been offered for open sale in shops in several 
EU countries based on the claim that they have little 
or no psychoactive effect because they contain less 
than the legal minimum level of THC and therefore 
are not controlled under drug laws. These and other 
products may claim to be high in CBD, which is not 
controlled under drug laws in most countries (e.g. in 
Finland it is classed as a medicinal product).
CBD may help to control the symptoms of epilepsy, 
but there are also claims that it is useful for treating 
a wide range of other illnesses or symptoms for 
which there is currently insufficient evidence to make 
a proper assessment. Any claims that they prevent or 
treat disease, or relieve symptoms, would bring these 
products under medicines law, which requires 
a licence for sale. The marketing of these products 
therefore often contains non-specific words or 
phrases, such as ‘health and well-being’, ‘wellness’, 
‘nutraceuticals’, etc. Food safety and other 
regulations may be required to regulate these 
products to ensure that they contain what it is 
claimed that they do. These products fall outside the 
scope of this publication.
l Summary
The regulation of cannabis and cannabinoids for medical 
purposes is a complex patchwork of approaches. At 
international level, the UN drug control treaties, under 
which the medical use of cannabis is very strictly limited, 
provide a backdrop to the regulatory frameworks for the 
medical use of cannabis and cannabinoids in all signatory 
countries. In addition, at EU level, the EMA is responsible 
for the scientific evaluation, supervision and safety 
monitoring of medicines, and it coordinates a network of 
national regulatory authorities.
There are three ways for medicines to receive cross-
national authorisation within Europe. One grants EU-wide 
access, and the other two can lead to authorisation in 
more than one EU country. To date, there have been no 
EU-wide marketing authorisations for cannabinoid-
containing medicines, although, for example, nabiximols 
has received approval in several EU countries using the 
alternative procedures. Medicines may also be authorised 
at national level. Regulatory procedures for new medicines 
consider evidence of both clinical effectiveness and safety. 
Regulatory authorities also undertake post-market 
monitoring of adverse events. Many of these 
pharmaceutical regulatory systems also have schemes 
that allow doctors to prescribe unapproved medicines 
under certain circumstances, often called compassionate 
use programmes. In many cases, these programmes are 
used to provide access to medicines for which trials are 
under way or the evidence is under evaluation.
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Part 3
What approaches to allowing the 
medical use of cannabis and 
cannabinoids have countries used?
This part of the report gives some examples of how various 
countries have made some form of cannabis or 
cannabinoids available for medical use, which products or 
preparations they have allowed and what legal and 
regulatory instruments they have used. These illustrate the 
variety of approaches taken and how these have evolved. 
A selection of European and international case studies are 
presented. The case studies have been selected to 
illustrate the range of regulatory frameworks applied, such 
as expanded versus exceptional access programmes, and 
the various products and preparations authorised. The 
North American schemes are described in some detail 
because they have been in operation the longest.
l How is the medical use of cannabis  and cannabinoids regulated in the United States and Canada?
North America was the first region to introduce the medical 
use of cannabis. This happened first in several states in the 
United States that passed citizen-initiated referenda to 
legalise medical use of cannabis in the mid-1990s. In 1999, 
the Canadian courts ordered the federal government to 
develop a national approach to the medical use of cannabis. 
The resulting programme was initially very restrictive but its 
operation was extended in response to a series of court 
challenges from patients who were dissatisfied with the 
access allowed under the initial scheme.
l Medical use of cannabis and cannabinoids in the United States
Types of products and preparations available for 
medical use
In the United States, the Food and Drug Administration 
(FDA) has approved various cannabinoids for medical use 
using the pharmaceutical regulatory path, namely on the 
basis of evidence from clinical trials that cannabinoids are 
safe and effective for medical use. Marinol was approved 
in 1985 by the FDA as an anti-emetic drug for cancer 
patients undergoing chemotherapy. Cesamet was 
approved in 1992 as an appetite stimulant in patients with 
AIDS-related wasting (Institute of Medicine, 1999).
Neither of these cannabinoids has been widely used in the 
United States. When taken orally, THC has a delayed onset 
of effect and patients often either do not achieve 
a therapeutic effect or experience adverse side effects that 
make them discontinue the drug (Grotenhermen, 2004; 
Iversen, 2007). This narrow therapeutic window (whereby 
blood concentrations that are effective are close to or 
overlap with those that produce symptoms of toxicity) is 
common to many other centrally acting medicines.
For a number of reasons, US pharmaceutical companies 
stopped developing new cannabinoids from the 1990s 
onwards. First, it is costly to develop and test new drugs, 
and it is difficult to recoup these costs for cannabinoids 
when many of the medical conditions for which they would 
be used are uncommon (Institute of Medicine, 1999). 
Chronic pain is more common but, as indicated in the 
review above, in clinical trials cannabinoids have proven to 
be only modestly effective analgesics. Second, the legal 
status of cannabis made it difficult to conduct research on 
the safety and effectiveness of cannabinoids. Third, there 
would be restrictions on the medical use of any approved 
cannabinoids, which might discourage physicians from 
prescribing them (Bostwick, 2012; Cohen, 2008; Institute 
of Medicine, 1999). However, in June 2018, the FDA 
approved Epidiolex, a CBD-based product developed by 
a company based in the United Kingdom, to treat patients 
2 years of age or older with epilepsy resulting from 
Lennox-Gastaut or Dravet syndrome (US FDA, 2018). 
These are rare conditions and it is too early to know how 
widely this product will be used.
In the United States, patient advocates used citizen-
initiated referenda to legalise the medical use of herbal 
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cannabis (known in North America as ‘medical marijuana’). 
They argued that patients’ reports of the medical benefits 
of using cannabis gave them a legal right to use cannabis 
for medical purposes, very broadly defined. Proposals to 
legalise the medical use of cannabis were put to the 
popular vote in citizen-initiated referenda, a procedure 
available in nearly half of US states that allows 
a proposition to be put on a ballot if it secures the 
signatures of a specified percentage of voters. If the 
proposition receives the majority of the vote, then the state 
legislature must enact legislation to make it state law.
An initiative to legalise the medical use of cannabis was 
passed in California in 1996 when voters supported 
Proposition 215 by 56 % to 44 %. This initiative allowed the 
medical use of cannabis for a broad set of indications that 
included nausea, weight loss, pain and muscle spasm, and 
any ‘serious medical condition’ for which cannabis might 
provide relief (Conboy, 2000). Over the next two decades, 
initially citizen-initiated referenda, and later legislation by 
state governments, allowed the medical use of cannabis in 
29 US states and the District of Columbia at the time of 
writing.
Availability issues
US states have varied in their definitions of the indications 
for the medical use of cannabis and in whether or not they 
have allowed patients to obtain cannabis from commercial 
dispensaries (Pacula and Smart, 2017; ProCon.org, 2017). 
The most restrictive state provisions only allow medical 
necessity as a defence against prosecution if a patient is 
arrested for using cannabis. Other states allow the medical 
use only of CBD-based cannabis preparations. Still other 
states allow the medical use of cannabis to be defined by 
doctors and patients, and permit medical cannabis to be 
sold in retail dispensaries to anyone with a medical 
recommendation (Pacula and Smart, 2017).
State-based laws on the medical use of cannabis have 
created regulatory issues for state and federal governments 
in the United States. State laws on the medical use of 
cannabis conflict with the US Federal Controlled Substances 
Act, which prohibits all uses of cannabis, including medical. 
Under the US Constitution, federal laws take precedence 
over state laws when the two conflict (Bostwick, 2012; 
Conboy, 2000; Hoffmann and Weber, 2010). The Bush 
administration enforced federal laws against cannabis 
sellers in states that allowed medical use. In 2009, the 
Obama administration announced that it would give a low 
priority to enforcing federal law in these states if they 
regulated the medical use of cannabis in ways that protected 
public health and order (Hoffmann and Weber, 2010). The 
administration continued to enforce federal laws against the 
cultivation and supply of cannabis on a commercial scale 
but refrained from prosecuting patients and doctors who 
complied with state laws (Eddy, 2009).
In many US states with laws allowing the medical use of 
cannabis, some physicians were reluctant to recommend 
it. They argued that in the absence of good evidence they 
found it difficult to decide who should be prescribed 
cannabis, in what doses and for how long (Barnes, 2000; 
Cohen, 2006; Hall and Degenhardt, 2003). Physicians 
were also concerned that they would be legally liable for 
any harms that patients experienced (Hoffmann and 
Weber, 2010; Pacula et al., 2004).
Patients often found it difficult to legally obtain cannabis in 
states that allowed medical use. In some states, they had to 
use the black market and in others they were allowed to grow 
their own, or have a carer grow it for them. State laws that 
allowed carers to grow for more than one patient enabled 
the development of cannabis buyers’ clubs that grew and 
sold cannabis to patients with a doctor’s recommendation. 
These clubs were not licensed to produce cannabis and so 
obtained it from the illicit market (Hoffmann and Weber, 
2010). The Obama administration’s decision not to enforce 
federal law in states that had authorised medical use 
effectively meant that states with liberal laws and 
dispensaries (California, Colorado and Washington State) 
had a quasi-legal market in which cannabis could be sold to 
any user who had a doctor’s recommendation (Cohen, 2010; 
Regan, 2011; Samuels, 2008).
l Medical use of cannabis and cannabinoids in Canada
In Canada, some cannabinoid medicines have been 
authorised for use, but cannabis has also been made 
available for medical use under special access schemes that 
have changed over time in response to patient pressure and 
court decisions.
With respect to authorised medicines, Sativex is approved for 
use for multiple sclerosis-associated spasticity under certain 
conditions. Additional indications include adjunctive 
treatment for the symptomatic relief of neuropathic pain in 
adult patients with multiple sclerosis, and adjunctive 
analgesic treatment in adult patients with advanced cancer 
who experience moderate to severe pain while on the highest 
tolerated dose of strong opioid therapy for persistent 
background pain. Nabilone is available for the treatment of 
severe nausea and vomiting associated with cancer therapy. 
Marinol was approved for AIDS-related anorexia associated 
with weight loss and for severe nausea and vomiting 
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Potential unintended consequences of the medical use of cannabis and cannabinoids
When considering the outcomes of regulatory changes 
to allow access to cannabis and cannabinoids for 
medical use, in addition to considering health risks and 
benefits for patients it is important to take into account 
the potential broader social and public health impacts. 
There is now a growing number of studies, primarily 
from the US, investigating these wider impacts. 
However, as with the evidence concerning the clinical 
effectiveness of various cannabis products and 
preparations, variations in approaches, definitions and 
data sources make drawing firm conclusions difficult, 
with studies often having contradictory outcomes or 
inconclusive results.
The EMCDDA is preparing a report that will provide an 
overview of evaluations of new regulatory models in the 
Americas, where some of these issues will be covered. 
In this box, we highlight some of the issues addressed 
in medical cannabis studies to date to illustrate the 
types of potential unintended consequences, both 
positive and negative, that may need to be considered 
when making cannabis or cannabinoids available for 
medical use. More details about the individual studies 
can be found in the background paper accompanying 
this report (Hall, 2018).
 ■ Impact on recreational use. Data from US 
household drug surveys suggest that cannabis use 
among adults over the age of 21 years may have 
increased between 2004 and 2012 after laws on 
the medical use of cannabis were passed (Wen et 
al., 2015). There were no differences in the 
prevalence of cannabis use among adults in states 
with and without laws on the medical use of 
cannabis, but adults in states with these laws were 
more likely to have used cannabis in the past 30 
days, to be daily cannabis users and to report 
symptoms of cannabis abuse/dependence than 
adults who lived in states that had not passed laws 
on the medical use of cannabis.
 ■ Use among young people. There is some concern 
that if medical cannabis laws make cannabis more 
available and send the message that cannabis use 
is not risky, use among young people might 
increase. However, comparisons of adolescent 
cannabis use in household and school-based 
surveys have generally not found any difference in 
use between US states that do and those that do 
not have laws on the medical use of cannabis (e.g. 
Ammerman et al., 2015; Cerda et al., 2012; Choo et 
al., 2014; Harper et al., 2012; Lynne-Landsman et al., 
2013; Schuermeyer et al., 2014; Wall et al., 2011, 
2012).
 ■ Accidental poisonings. Studies into cannabis 
poisonings among young children and acute 
healthcare contacts raise concerns about the 
potential for increases in accidental poisonings 
(Wang et al., 2016, 2017). The accidental poisonings 
of very young children highlight the importance of 
child-proof packaging and regulations around sales 
to minors when establishing these programmes.
 ■ Cannabis-related motor vehicle fatalities. There 
have been mixed results from studies of the effects 
of laws on the medical use of cannabis on cannabis-
related motor vehicle fatalities. Some studies (e.g. 
Masten and Guenzburger, 2014) have found 
increased involvement of cannabis-impaired drivers 
in fatal crashes in states that have passed laws on 
the medical use of cannabis. Other studies have not 
(e.g. Anderson et al., 2013).
 ■ Suicides. Anderson et al. (2014) reported steeper 
declines in suicides among males aged 20 to 
30 years in US states that legalised medical use of 
cannabis than in those that had not, but other 
studies that took account of differences between 
states (Grucza et al., 2015) or looked at the 
association between suicide rates and the number 
of patients using cannabis for medical purposes did 
not support this finding (Rylander et al., 2014).
 ■ Substitution of medical cannabis for other 
substances. An important issue is whether medical 
cannabis may be substituted for other, potentially 
more risky, substances. An analysis of opioid 
overdose deaths in the US found smaller increases in 
these deaths in states with laws on the medical use 
of cannabis than in those without such laws, and the 
difference appeared to increase over time 
(Bachhuber et al., 2014). Better evidence is needed 
that cannabis has been substituted for opioids in this 
way and that the association cannot be explained by 
other policy differences between states that have 
and have not passed laws on the medical use of 
cannabis (e.g. rates of imprisonment of opioid users 
and provision of methadone-assisted treatment) 
(Campbell et al., 2018; Hayes and Brown, 2014).
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associated with cancer chemotherapy. It was withdrawn from 
the Canadian market by the manufacturer in February 2012, 
but this was not for safety reasons (Abuhasira et al., 2018).
In addition, Canada was one of the first countries to establish 
a national programme for the medical use of cannabis. In 
1999, the federal government established an exceptional 
access scheme that required the minister to approve each 
patient. Court actions by patients who complained that the 
system was too restrictive ensured that the programme 
evolved over the next two decades from an exceptional 
access scheme to an expanded access programme like that 
in California (Freckelton, 2015; Ries, 2016).
In 1998, a patient with HIV argued in court that he should be 
exempted from criminal prosecution to allow him to use 
cannabis to treat his illness and in June 1999, the health 
minister published guidance on allowing exemptions from 
criminal prosecution in exceptional cases. However, these 
exemptions were based on ministerial discretion. In 2000, the 
Ontario Superior Court of Justice ruled that the federal 
prohibition on cannabis use, without a well-defined and 
functioning exemption for medical use, violated the rights of 
a patient with intractable epilepsy under the Canadian 
Charter of Rights and Freedoms. The court ruled that the 
government should allow patients to use cannabis for medical 
purposes and that it should provide a legal supply of cannabis 
so that doctors could prescribe cannabis to their patients.
In April 2001, the Canadian government legislated to allow 
patients to access cannabis for medical purposes 
(Bogdanoski, 2010; Lucas, 2008) if they (1) had a terminal 
illness and a life expectancy of less than 12 months; (2) had 
multiple sclerosis, a spinal cord injury or disease, cancer pain, 
AIDS, arthritis or epilepsy; or (3) had another ‘serious medical 
condition’ that had failed to be relieved by ‘conventional 
treatments’ (Lucas, 2012; Moffat, 2002). Patients with these 
conditions (or a carer) could obtain cannabis from the 
government, or obtain a licence to grow cannabis for their 
own medical use or have a carer grow it on their behalf.
Relatively few patients used this scheme. There were, for 
example, an estimated 290 000 patients using cannabis for 
medical purposes in British Columbia in 2007 (Lucas, 2008), 
but only 1 816 had approved access to medical cannabis and 
only 356 obtained cannabis from the government (Fischer et 
al., 2015). The remainder were licensed to grow cannabis 
because they were dissatisfied with the quality and cost of 
the government cannabis (Lucas, 2008). This regulatory 
system was also successfully challenged in court in 2008. 
New legislation in March 2014 licensed more cannabis 
producers, allowed doctors greater latitude in prescribing, 
removed federal oversight of prescribing and permitted 
patients to receive cannabis directly from licensed producers 
(Ablin et al., 2016). The cost of herbal cannabis (estimated to 
be CAD 500 (approximately EUR 330) a month) was not 
covered by health insurance (Ablin et al., 2016).
Under all variations of Canadian policy, doctors have been 
reluctant to prescribe cannabis (Ablin et al., 2016; Lucas, 
2012). The Canadian Medical Association and the Canadian 
Medical Protective Association advised physicians against 
doing so (Abraham, 2002; Lucas, 2008; Ries, 2016) because 
there was a lack of evidence that cannabis was effective for 
most of the requested indications and prescribers could be 
sued if their patients experienced adverse effects (Lucas, 
2012). The fact that most physicians were reluctant to 
prescribe cannabis created a market niche for doctors who 
were prepared to prescribe cannabis for a fee (Ablin et al., 
2016).
l What approaches have been used to allow the medical use of cannabis or cannabinoids in the European Union?
Novel policy approaches to the medical use of cannabis in 
the United States and Canada have prompted other 
countries, including some in Europe, to allow patients to 
use cannabis and cannabinoids for medical purposes (4). 
The most common initial approach has been to use some 
form of special access scheme, typically by creating 
a system that provides medical approval and oversight, 
limits medical use to a restricted set of medical conditions, 
and often restricts the cannabis preparations that patients 
can use. The decision to subsidise or reimburse patient 
costs, or expect them to pay full price, for the medicine or 
preparation will also have an impact on the extent of use.
Medicinal products containing cannabinoids are authorised 
for use in many EU countries (Abuhasira et al., 2018; 
Bramness et al., 2018; Krcevski-Skvarc et al., 2018). Table 2 
shows that medicinal products containing nabiximols are 
available in the majority of EU countries. Medicinal products 
containing dronabinol and nabilone are less widespread, 
available in around one third of EU countries. In some of 
these countries, national health insurance systems will 
reimburse the cost under certain conditions, such as prior 
approval or prescription by a specialist. Epidiolex has not 
been authorised for use in Europe; the EMA’s decision on 
this was under review in 2018.
(4) National regulatory frameworks are complicated and there may 
sometimes be a lack of clarity on both the details of the different approaches 
and how they operate in practice. In addition, they evolve over time and 
experts sometimes disagree on how frameworks should be legally 
interpreted.
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TABLE 2
Availability of cannabinoid-containing medicinal products in the European Union, Turkey and Norway
Medicinal products containing Comment
dronabinol nabilone nabiximols
Belgium No No Yes
Bulgaria No No No
Czechia No No Yes Sativex has a marketing authorisation but is not 
traded.
Denmark Yes Yes Yes Medicinal products containing nabilone and 
dronabinol on compassionate grounds.
Germany No Yes Yes There is no marketing authorisation for medicinal 
products containing dronabinol, but dronabinol 
is available in magistral preparations.
Estonia No No Yes The Estonian State Agency of Medicines (ESAM) 
may authorise use based on an application by 
a doctor for a specific patient. A medicines 
wholesaler needs to submit an application for 
the import of the medicinal product, which is 
evaluated by the ESAM. Three applications for 
Sativex have been submitted (two were 
approved).
Ireland Yes Yes Yes Medicinal products containing nabilone and 
dronabinol are not authorised for marketing, but 
can be prescribed and imported.
Greece No No No
Spain Yes Yes Yes Medicinal products containing dronabinol and 
nabilone in exceptional cases (imported).
France Yes No Yes Medicinal product containing dronabinol by 
temporary authorisation. A marketing 
authorisation was granted for Sativex in January 
2014, but it has not been marketed yet.
Croatia Yes Yes Yes No marketing authorisation for medicinal 
products, but they can be imported based on 
individual prescriptions.
Italy No No Yes
Cyprus No No No
Latvia No No No
Lithuania No No Yes Nabiximols for clinical trials only.
Luxembourg No No Yes
Hungary No No No
Malta No No Yes Sativex has a marketing authorisation but is not 
traded.
Netherlands No No Yes
Austria No Yes Yes There is no marketing authorisation for medicinal 
products containing dronabinol, but dronabinol 
is available in magistral preparations.
Poland Yes Yes Yes Sativex has a marketing authorisation. The other 
two products do not, but they can be made 
available to patients through a special permit 
(named-patient import).
Portugal No No Yes
Romania No No No
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Medicinal products containing Comment
dronabinol nabilone nabiximols
Slovenia Yes Yes Yes Sativex, Marinol and Cesamet have no marketing 
authorisation, but they can be made available to 
patients through special permit (named-patient 
import).
Slovakia No No No Sativex was authorised but the marketing 
authorisation expired in June 2017.
Finland No No Yes
Sweden Yes No Yes Dronabinol: special permission on a named-
patient basis. No legal objections for nabilone (if 
for a medicinal purpose and for personal use), 
but no special permission on a named-patient 
basis has been applied for in the last 3 years.
United Kingdom No Yes Yes
Turkey No No Yes
Norway Yes Yes Yes Medicinal products containing dronabinol and 
nabilone: compassionate use for a named 
patient.
NB: In several countries, cannabinoid-containing medicinal products have no marketing authorisation, but are available through a variety of schemes (under 
medical supervision) that allow patients to access medicines that have no formal marketing authorisation (see Part 2). This table is based on Abuhasira et al. 
(2018), Bramness et al. (2018), Krcevski-Skvarc et al. (2018) and feedback from the EMCDDA network of legal and policy correspondents. Epidiolex (CBD) has 
not been included in this exercise, but may be available in some countries through compassionate use programmes.
It is uncommon in the European Union for the use of raw 
herbal cannabis for medical purposes to be permitted. 
Some countries allow patients to access standardised 
cannabis preparations (either imported or cultivated 
domestically). Other countries give patients access to 
cannabis for medicinal purposes in the form of magistral 
preparations (i.e. raw cannabis transformed into final 
consumption format by a pharmacist) (Figure 2).
Several European countries have established some form of 
exceptional/compassionate use programme or other 
special access scheme to allow access to cannabis 
preparations for the treatment of a narrow range of 
medical conditions. Countries that currently have such 
programmes include Croatia, Denmark, Finland, Norway, 
Poland and Sweden. Four European countries have an 
established access programme: Czechia, Germany, Italy 
and the Netherlands. Both Luxembourg and Portugal 
passed laws on the medical use of cannabis in 2018, but 
details on implementation were not available at the time of 
writing.
FIGURE 2
Availability of cannabis preparations for medical use in 
the European Union and Norway
Standardised cannabis 
preparations
Magistral preparations 
only
No cannabis 
preparations 
allowed
NB: In the majority of countries where standardised cannabis preparations are 
available, magistral preparations are also permitted: Estonia, applications for 
standardised preparations need to be submitted to the Estonian State Agency of 
Medicines; Finland, medical use partially allowed; Sweden and Norway, only 
a small number of patients have been granted permission to use cannabis 
preparations; Poland, at the time of writing, standardised cannabis preparations 
are not available, but approval was given to a supplier. In the case of Portugal, at 
the time of writing, no details were available on the implementation of the 
Portuguese law on the medical use of cannabis, which was adopted in July 2018. 
Similarly, the UK situation was under review at the time of writing. This figure is 
based on Abuhasira et al. (2018), Bramness et al. (2018), Krcevski-Skvarc et al. 
(2018) and feedback from the EMCDDA network of legal and policy 
correspondents.
TABLE 2 (continued)
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l Medical use of cannabis and cannabinoids in the Netherlands
The Dutch framework is an example of a long-established 
system that allows relatively broad access to cannabinoid 
medicines and cannabis preparations, with any doctor 
allowed to prescribe.
In the Netherlands, nabiximols-containing medicinal 
products are available as authorised medicines. However, 
since 2003, Dutch law has also permitted any doctor to 
prescribe herbal cannabis to treat symptoms of medical 
conditions including, but not limited to, multiple sclerosis, 
HIV, cancer, pain and Tourette syndrome. Guidelines from 
the Office of Medicinal Cannabis in the Ministry of Health, 
Welfare and Sport recognise that there have been positive 
experiences with many other indications, and allow the 
doctor to judge if cannabis will help a patient’s condition. 
A doctor should prescribe cannabis only if the standard 
treatments and registered medicines have not had the 
desired effect or are causing too many side effects.
Under the Dutch scheme, cannabis is produced under 
licence by a private company, Bedrocan, to meet quality 
standards. It is dispensed by a pharmacist to patients with 
a medical prescription (Bogdanoski, 2010). The company 
manufactures five products, with various THC and CBD 
levels, in dried flower and granulated form. This company 
has also been supplying several other European countries 
that have started new programmes for the medical use of 
cannabis.
Patient characteristics have been reported in two studies. 
Hazekamp and Heerdink (2013) reported the 
characteristics of 5 540 patients who were prescribed 
cannabis for medical purposes in the Netherlands 
between 2003 and 2010. The incidence of new users 
peaked at 5 per 100 000 in the first 2 years of the scheme 
and declined thereafter to 3 per 100 000. The annual 
prevalence of the medical use of cannabis varied between 
8 and 10 per 100 000 between 2005 and 2010. The drugs 
co-prescribed to the Dutch patients suggested that 
cannabis was used primarily to treat chronic pain. More 
recently, de Hoop et al. (2018) have provided information 
on the patients who accessed cannabis under the scheme 
between 2013 and 2016. The prevalence of the medical 
use of cannabis increased from 6.9 per 100 000 in 2010 to 
24.6 per 100 000 in 2016. The proportion of female 
patients marginally declined (from 57 % to 51 %) but there 
was no change in age, mean daily dose of cannabis 
(0.64 g vs. 0.73 g) or average duration of use (251 and 
254 days). The authors attributed the increased prevalence 
to the fact that cannabis oils have also been permitted 
since 2015.
l Medical use of cannabis and cannabinoids in Czechia
Czechia operates a policy that illustrates how a country may 
permit cannabinoid medicines and cannabis for medicinal 
purposes in a strictly limited way. In Czechia, medicinal 
products containing dronabinol or nabilone are not available 
as authorised medicines. Sativex is an authorised medicine, 
but it is not reimbursed by the national health system or 
social insurance companies and it is currently not traded.
Czechia does allow patients to use cannabis preparations 
for medical purposes. A law allowing individuals to use 
herbal cannabis for medicinal purposes was passed in 
December 2013. Only a limited number of medical 
indications qualify for prescription (cancer, Parkinson’s 
disease, multiple sclerosis and psoriasis), as set out in 
a ministerial notice of 2015. Prescription is limited to 
specially qualified doctors (currently 57), such as 
oncologists and psychiatrists. Dispensing is limited currently 
to 41 pharmacies. Since 2018, the maximum amount that 
can be prescribed to a patient has been 180 g per month. 
The supply initially came from Bedrocan in the Netherlands, 
but domestic cultivation by a monopoly producer now 
provides defined varieties of cannabis to the government for 
distribution. The first domestic harvest was delivered to 
pharmacies in March 2016. The final price to the patient is 
approximately EUR 3.70 per gram, which is not reimbursed 
by the national health system or social insurance companies.
l Medical use of cannabis and cannabinoids in Croatia
The policy in Croatia provides greater access to medical 
cannabinoids and cannabis than in Czechia, but less than 
in Germany or the Netherlands.
In Croatia, medicinal products containing dronabinol, 
nabiximols and nabilone are available, with the former 
prescribed for symptoms of cancer and AIDS. Neither is 
reimbursed by national health or social insurance 
companies. There is no marketing authorisation for these 
products, but they can be imported based on prescriptions 
for individual patients issued by selected primary 
healthcare physicians following the recommendation of 
a specialist physician.
As a result of media and public pressure in support of 
some patients, in October 2015 the national law was 
changed to permit medicines that contain THC to be 
prescribed, including preparations of plant material. Only 
a limited number of medical indications qualify for 
prescription, namely multiple sclerosis, cancer, epilepsy 
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and AIDS. Although an initial recommendation is needed 
from a neurology, infectious disease or cancer specialist, it 
is possible for any general or family practitioner to write 
the prescription. The prescription should state the amount 
of THC in a single dose, the number of individual doses, 
drug form, dosage and method of use and, if applicable, 
also specify the type of herbal drugs and herbal 
preparation that should be used. The quantity prescribed 
may be sufficient for up to 30 days’ use, up to a maximum 
allowable amount of 7.5 g of THC. Tilray products are 
imported to Croatia and are not reimbursed.
l Medical use of cannabis and cannabinoids in Germany
The German legal framework developed over several years 
as a result of court challenges to the state (5). The result is 
a policy that provides broad access to cannabinoids and 
cannabis for medical purposes.
In Germany, medicinal products containing nabilone and 
nabiximols are available on prescription; they may be 
reimbursed by national health or social insurance 
companies.
In March 2017, the ‘Cannabis as Medicine’ Act created 
a mechanism for quality-controlled cannabis supply, 
including domestic production. Patients for whom all other 
treatment options have been exhausted can get a medical 
prescription for dried cannabis flowers and extracts of 
standardised quality at a pharmacy. The prescription of 
cannabis preparations is not limited to certain specialists, 
nor is their use limited to specific medical indications.
The 2017 Act allows cannabis to be prescribed for any 
life-threatening illness, or one that will affect the patient’s 
quality of life permanently because of severe health 
problems. It allows for up to a maximum of 100 g per 
month, and insurance companies must cover these costs 
for chronically and terminally ill patients.
To establish domestic production and to ensure that the 
cannabis preparations supplied are of standardised quality, 
a government ‘cannabis agency’ was set up. In April 2017, 
a tender went out for 10 companies to grow approximately 
(5) In 2000, eight patients with different medical conditions won their cases 
before the Federal Constitutional Court to get legal access to cannabis plant 
material. By 2007, the Federal Ministry of Health’s Federal Institute for Drugs 
and Medical Devices was allowing local pharmacies to sell imported 
cannabis flowers and extracts. Around 900 patients received an approval, 
but they claimed that imported cannabis was not affordable.
2 000 kg of cannabis for medicinal purposes, but 
production is unlikely to start before 2019.
l Medical use of cannabis and cannabinoids in Italy
The policy in Italy shows how a country may limit medicinal 
products while investing in the production of standardised 
cannabis preparations. Medicinal products containing 
dronabinol or nabilone are not authorised; the only 
authorised cannabinoid medicinal product is Sativex, 
which is reimbursed under the national health insurance 
scheme.
In 2007, a Decree of the Ministry of Health scheduled 
natural and synthetic cannabinoid derivatives in the list 
of substances with therapeutic activity, allowing them to 
be prescribed. In 2013, cannabis plant extracts and 
active compounds of plant origin were added to the list, 
allowing doctors to prescribe cannabis preparations for 
medical use. In 2015, the medical indications were 
clarified as including multiple sclerosis pain, chronic pain 
resistant to conventional treatment, and nausea, 
vomiting and cachexia associated with cancer or HIV. 
Any doctor can prescribe for medical use and the 
preparations can be made in any pharmacy, in 
accordance with a medical prescription for an individual 
patient. Cannabis extracts should be administered only 
orally, by infusion or in oil, or by inhalation, not by 
smoking. Currently, it is estimated that 9 000-10 000 
patients receive cannabis for medical use. Initially, 
Bedrocan products were imported from the Netherlands, 
and in 2017 280 kg was imported. However, domestic 
growing started in 2014 at a secure state pharmaceutical 
facility under the supervision of the Ministry of Health, 
with an expected yield of 100 kg per year. Distribution 
started at the end of 2016.
The cannabis is cultivated from two plant varieties and is 
certified for good agricultural practice and good 
manufacturing practice. The standardised cannabis 
preparations are available in two formulations, FM1 
(13-20 % THC and <1 % CBD) and FM2 (6 % THC and 8 % 
CBD), with both products priced at approximately EUR 42 
for 5 g.
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l Examples of approaches taken by some other countries to allow the medical use of cannabis and cannabinoids
l Medical use of cannabis and cannabinoids in Israel
The case of Israel offers an example of a system in which 
one cannabinoid medicine is authorised and reimbursed, 
and policies on the use of herbal cannabis as medicine 
have evolved over time. Health professionals have played 
an important role in the development of the medical use of 
cannabis and cannabinoids in Israel. The number of 
medical indications for which herbal cannabis is allowed is 
limited, but Israel, unlike EU countries, permits patients to 
smoke it. New regulations in 2016 aimed to raise and 
standardise the quality of the supply, prescription and 
clinical practices. They have led to an increase in the 
number of patients registered, by requiring only standard 
rather than special prescriptions and by permitting the 
distribution of cannabis by pharmacies rather than 
growers as before.
In Israel, medicinal products containing dronabinol and 
nabilone are not available as authorised medicines. Sativex 
is authorised for treating moderate to severe spasticity in 
multiple sclerosis and as an adjunctive treatment for 
cancer pain. It is reimbursed by health insurance 
companies or the state social security system.
Israel was one of the first countries outside North America 
to allow the medical use of cannabis, under the approval 
and oversight of what is now the Israeli Medical Cannabis 
Agency (IMCA) within the Ministry of Health. The IMCA 
authorises growers to produce cannabis (nine growers as 
at February 2018). For some years it was sold directly to 
patients, but following the 2016 regulations the growers 
supply it to registered pharmacies. The cannabis is supplied 
as an oil or as dried flowers for smoking or vaporisation. It 
contains 12 % THC and an amount of CBD specified by the 
physician. Also following the 2016 regulations, cultivators 
and processors should follow the IMCA ‘Medical Grade 
Cannabis Cannacopeia’ guide to good agricultural, 
manufacturing, distribution, security, and clinical practices. 
Only 30 physicians are authorised to prescribe cannabis, 
though the 2016 regulations have proposed a standardised 
training course that should increase this number. Herbal 
cannabis is not publicly subsidised, and patients pay 
approximately 30 EUR for 10 grams.
Since July 2014, permits to use cannabis have been 
allowed for a short list of medical indications, and only 
when a physician has indicated that a patient has failed to 
respond to recognised treatments. The approved 
indications include cancer treatment; inflammatory bowel 
disease; neuropathic pain after more than a year of 
treatment in a pain clinic; AIDS-related cachexia; 
neurological diseases such as multiple sclerosis, 
Parkinson’s disease and Tourette syndrome; post-
traumatic stress disorder; and terminal illnesses. The 
Israeli programme also lists the following contraindications 
for the medical use of cannabis: congestive heart failure, 
psychosis, anxiety disorder, having a first-degree relative 
with a psychiatric disorder (especially one with onset 
under the age of 30 years), and a personal history of drug 
abuse or addiction.
In exceptional circumstances, Israeli patients can use 
cannabis for other medical conditions if an expert 
physician requests an ‘exceptional approval’. The physician 
must make a detailed case to the medical cannabis unit, 
describe how they would assess the patient’s response to 
cannabis and indicate that they would report any adverse 
events (Ablin et al., 2016).
There are limited data on the number of patients receiving 
cannabis in Israel. The Ministry of Health indicated in 2013 
that 8 713 patients had been granted a licence to use 
cannabis for medical purposes, including 1 518 with 
cancer and 4 864 with chronic pain. Waissengrin et al. 
(2015) presented data on cancer patients treated with 
cannabis in a major Israeli cancer hospital. These included 
270 patients who had obtained a permit to use cannabis 
for medical purposes out of an estimated 17 000 patients 
who were treated at the hospital in 1 year (1.7 % of 
patients). They received cannabis to treat pain, loss of 
appetite and nausea. Nearly half (46 %) died within 
6 months of initiating treatment. Among those still alive at 
6 months, 46 % renewed their medical cannabis permits. 
The authors attributed the low rate of uptake in this 
hospital to physicians’ reluctance to prescribe cannabis 
and patients’ reluctance to use an illicit substance; such 
physician reluctance has also been reported elsewhere. 
However, attitudes may be changing with experience in 
prescribing cannabis (Sharon et al., 2018) and as the new 
training programme for physicians is implemented. The 
number of licensed medical cannabis patients has 
increased in recent years, reaching 28 000 patients with 
valid licences in March 2017 (Zarhin et al., 2017).
l Medical use of cannabis and cannabinoids in Switzerland
The Swiss model, dating from 2011, is an example of 
a system that restricts the prescriber’s choice to either an 
approved medicinal cannabinoid product or a magistral 
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cannabis preparation and restricts prescriptions to 
applicants on a named-patient basis. Although the 
qualifying medical conditions are not individually 
identified, they are specified as ‘potentially life-
threatening’.
In Switzerland, dronabinol (by special permit) and 
nabiximols are available as authorised medicines. 
Reimbursement for nabiximols is on a case-by-case basis 
on request to the insurance company.
In 2011, Switzerland legislated to allow the medical use of 
cannabis in exceptional circumstances under the 
supervision of the Swiss Federal Office of Public Health 
(Kilcher et al., 2017). Doctors must request a licence for 
each patient that enables the patient to use either 
a commercially available synthetic THC (dronabinol) or 
a tincture of Cannabis sativa containing 5 % of THC 
prepared by a pharmacist. The prescriber has to document 
that the patient has a potentially life-threatening condition, 
describe the likely benefit from THC and include evidence 
that the patient has provided informed consent to using 
the cannabis product.
Kilcher et al. (2017) reported data on patients treated 
under this scheme in 2013 and 2014. Only 8 of 1 656 
requests were rejected, and 1 193 patients were treated 
(542 in 2013 and 825 in 2014) by 332 internal medicine 
specialists (55 %) and neurologists (14 %). Most patients 
(91 %) paid USD 400-500 per month because these drugs 
were not covered by insurance. Just over half (57 %) were 
female, with a mean age of 57 years. The main diagnoses 
were neurological disorders (49 %), musculoskeletal 
disorders (25 %) and cancers (10 %), and the main reasons 
for use were chronic pain (49 %) and spasticity (40 %). 
Most patients (62 %) took no other medication. When they 
did, analgesics were the most commonly used medicines. 
Licences were given for 6 months but could be extended 
and the proportion that were extended increased from 
26 % in 2013 to 39 % in 2014.
In July 2018, the Federal Office of Public Health 
announced its intention to broaden access to the scheme, 
with a new law to be proposed by summer 2019.
l Medical use of cannabis and cannabinoids in Australia
In 2016, the Australian federal government legislated to 
enable patients to obtain unapproved cannabis products 
for medical use under the special access provisions of the 
Therapeutic Goods Act (Freckelton, 2015). State 
governments in New South Wales, Queensland and 
Victoria have also made legislative changes that permit 
medical cannabis use and the cultivation of cannabis for 
medical use.
The Australian programme for the medical use of cannabis 
met with considerable resistance from oncologists, 
neurologists and pain specialists, who are the only medical 
practitioners who can initiate treatment. These specialists 
argue that there is little evidence to support the medical 
use of cannabis and that much better treatments are 
available for chemotherapy-induced nausea and vomiting, 
neuropathic pain, muscle spasticity and epilepsy (see, for 
example, ANZCA Faculty of Pain Medicine, 2015; Cancer 
Council Australia and Clinical Oncology Society of 
Australia, 2016; Martin et al., 2018). Prescribers’ legal 
liability for any harm caused to patients is also a concern. 
Patients have therefore found it difficult to obtain 
a prescription for cannabis. Patients also complain about 
the complex approval process produced by overlapping 
federal and state/territory requirements. Critically for 
many patients, the Australian healthcare system does not 
cover the costs of importing cannabis products. Patients 
therefore have to pay the substantial costs of importing 
the drug, for example AUD 400 (around EUR 250) per 
month for pharmaceutical-grade CBD to treat epilepsy.
l Summary and discussion
It is clear that no standard regulatory framework for 
cannabis preparations and cannabinoid products has been 
developed and that there is considerable variation 
between countries in the approaches taken, reflecting 
a variety of historical and cultural factors. In most 
countries, the provision of cannabis and cannabinoid 
products and preparations for medical purposes has 
evolved over time, often in response to patient demand or 
product developments, and the situation continues to 
change rapidly. Nevertheless, in general three broad types 
of approach can be seen, although often countries will use 
more than one of these in parallel.
Allowing the use of medicinal products containing 
cannabinoids
As described above, several pharmaceutical cannabinoids 
have been approved for medical use (e.g. Marinol and 
Cesamet), but in general these are not widely used 
because patients find it difficult to achieve the desired 
therapeutic benefits without also experiencing unwelcome 
psychoactive effects. In addition, some of these drugs 
resulted in limited financial returns for the companies that 
marketed them, and this may have slowed down product 
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development. Sativex and Epidiolex have since been 
developed and approved for medical use in neuropathic 
pain and intractable epilepsy, respectively, on the basis of 
evidence of their effectiveness from RCTs. In addition, 
clinical trials of some standardised cannabis preparations 
are under way, so in the future some of these may also 
receive market authorisation as pharmaceutical products.
However, many governments are faced with demand from 
patients who want to use cannabis and cannabinoids to 
treat symptoms of illnesses for which there is currently 
little or no evidence of efficacy or safety. This includes 
many of the conditions for which cannabis is reportedly 
used in countries that have schemes that provide wide 
access, namely anxiety disorders, depression, sleep 
problems, other neurological conditions, cancers and 
inflammatory bowel diseases. Currently, there are 
insufficient clinical trial data on which to base approval of 
their use in treating these conditions, which may cause 
patients to resort to black market cannabis products. This 
has led to the development in some countries of 
alternative methods of providing access to cannabis and 
cannabinoids.
Allowing the medical use of unauthorised products or 
preparations
Special access schemes to allow the medical use of 
unauthorised products or preparations take a number of 
forms. In some cases, the medical use of cannabis may be 
allowed under some variation of a special access scheme 
for unapproved medicines as an interim measure while 
awaiting the results of clinical trials or pending 
authorisation. This approach has been taken in, for 
example, Australia, Israel and the Netherlands. These 
schemes allow doctors to prescribe cannabis and 
cannabinoids as unapproved medicines for various 
medical purposes.
Other schemes allow cannabis and cannabinoids to be 
supplied to patients on prescription, often on 
compassionate grounds. Some schemes restrict use to 
medical conditions for which there is evidence of efficacy 
(e.g. nausea and vomiting, muscle spasticity and chronic 
pain). Sometimes access is approved on a case-by-case, 
named-patient basis. Some schemes restrict the cannabis 
products that can be used to pharmaceutical-quality 
cannabinoids or standardised plant extracts. Others allow 
the use of herbal cannabis products that have been 
standardised and quality controlled. In general, these 
schemes still parallel the regulatory approach for 
medicinal products.
A major challenge in many of these approaches has been 
physicians’ reluctance to prescribe cannabis for ethical 
and medico-legal reasons. Patients also complain about 
cumbersome approval processes, the quality and the cost 
of the cannabis and cannabinoids that are available, and 
restrictions on the cannabis products that they are allowed 
to use.
De novo stand-alone medical cannabis programmes
Some stand-alone medical cannabis programmes have 
been established outside the medicines regulatory 
systems. For example, in the United States, the regulatory 
requirements for medicines have been avoided by passing 
citizen-initiated referenda that allow patients to smoke 
cannabis and use other cannabis products for very broadly 
defined medical reasons. Physicians have sometimes been 
reluctant to ‘recommend’ cannabis under such schemes 
because of uncertainty about clinical indications and fear 
of being held legally liable for any harm that patients may 
experience. In some US states, this issue has been 
circumvented by legalising the commercial supply of 
cannabis through dispensaries. 
In general, these stand-alone schemes do not facilitate the 
conduct of clinical trials and the establishment of an 
evidence base on which to assess the benefits and harms 
of medical use of cannabis and cannabinoids. Other 
methods, which might include large-scale cohort studies 
using record linkage or the establishment of registries for 
medical cannabis users to monitor rates of continuation 
and adverse events, are needed. Government funding of 
such studies may be required.
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Part 4
What are the regulatory challenges in 
allowing the medical use of cannabis 
and cannabinoids?
Many EU countries now allow, or are considering allowing, 
the medical use of cannabis or cannabinoids in some form. 
However, the approaches taken to making these available 
are very variable, in terms of both the medicinal products 
and preparations allowed and the regulatory frameworks 
governing their provision. Consideration of these diverse 
approaches highlights a number of key issues that need to 
be addressed as part of any process for making cannabis 
or cannabinoid-containing products or preparations 
available for medical use.
Medicinal products that have followed the pharmaceutical 
regulatory path (including Cesamet, Marinol, Sativex and 
Epidiolex) will have had many decisions predetermined by 
that process, such as doses, indications and routes of 
administration. However, when countries are considering 
allowing cannabis preparations for medical use, these and 
a number of other regulatory issues need to be considered. 
Key issues include:
 ■ What types of medicinal products or cannabis 
preparations should be allowed? Governments can 
decide to allow only medicinal products that have 
followed the pharmaceutical regulatory path and are 
authorised for marketing in the country. Governments 
can also consider giving access to unauthorised 
products and preparations through a range of other 
mechanisms, such as exceptional use, compassionate 
use and named-patient or expanded access 
programmes (see Part 2 of this report).
 ■ What forms of cannabis preparations should be 
allowed? Governments might consider allowing raw 
cannabis; magistral preparations made by 
a pharmacist; other cannabis preparations, such as 
standardised cannabis extracts; cannabis oils; and/or 
other forms of cannabis.
 ■ What routes of administration for cannabis 
preparations should be allowed? Cannabis can be 
manufactured as oral preparations, such as capsules or 
oils; as preparations that can be vaporised; or in other 
forms.
 ■ For which medical conditions should treatment with 
cannabis preparations or medicinal products be 
permitted? Governments could consider authorising 
cannabis preparations to treat only medical conditions 
for which there is evidence of efficacy (e.g. nausea and 
vomiting, muscle spasticity and chronic pain) or they 
might consider, under certain preconditions, approval 
for any condition in which some patients have reported 
benefits.
 ■ If cannabis preparations were to be made available, 
would they require a prescription? If so, who would be 
authorised to prescribe (e.g. only specialist physicians, 
any medical practitioner and/or nurse prescribers)?
 ■ If cannabis is made available for medical use, how will 
governments address the possible reluctance of 
physicians to prescribe cannabis for ethical or medico-
legal reasons and uncertainty about clinical indications 
and dosing, particularly where any physician is 
authorised to prescribe cannabis preparations? Would 
guidelines and training be provided, and, if so, by 
whom?
 ■ For any scheme proposed, how much of the cost will be 
met by patients? Will medicinal products or cannabis 
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preparations be reimbursed to patients? Will the cost of 
these medicinal products or cannabis preparations be 
covered by the national healthcare system or health 
insurance schemes?
 ■ How should cannabinoids fit into existing treatment for 
those medical conditions for which they may be used 
(e.g. as an adjunctive treatment or as a first-line 
treatment)?
 ■ How might prescriptions be limited? How should 
monitoring of patient outcomes and adverse events be 
carried out, and by whom?
 ■ What type of quality standards should be applied? If 
cannabis is to be grown at home for medicinal 
purposes, will any standards be applicable, and how will 
they be enforced?
 ■ If cannabis is to be an active substance in the 
manufacture of cannabis preparations such as oils or 
capsules, will the manufacturer comply with the 
relevant quality standards, such as EU good 
manufacturing practice and good distribution practice 
standards?
 ■ How might governments permit the manufacturing and 
distribution of cannabis for medical purposes? Should 
governments contract private companies? Might 
patients be allowed to grow their own cannabis for 
medical purposes? How should cannabis be distributed 
to patients? Could this be done through any pharmacy, 
specific pharmacies or other distribution channels?
 ■ How will the necessary pharmacovigilance schemes 
and data collection for reporting to the INCB be 
organised?
 ■ Will data systems be established to collect evidence on 
the wider public health and societal outcomes of the 
regulatory changes and to help in strengthening the 
evidence base? How will this be organised and what 
roles might government, research bodies and industry 
play in this (e.g. by facilitating or conducting large-scale 
cohort studies or establishing patient registries)?
 ■ In the European Union, consideration may need to be 
given to potential cross-border patient access issues 
that might arise where neighbouring countries have 
different national schemes.
The above list is not exhaustive. It highlights the complexity 
of any decision-making about making cannabis or 
cannabinoids available for medical use. Consideration 
needs to be given to multiple issues along the whole chain 
of events from product development through production 
and distribution to monitoring outcomes for both safety 
and effectiveness. In what is a very fast-moving field 
characterised by an often hotly contested debate, this 
report has sought to provide an objective look at current 
evidence, practice and experience. It illustrates the 
diversity of approaches currently being taken and points to 
the importance of developing an agreed conceptual 
framework and terminology to assist in building a base for 
assessing the medical use of cannabis and cannabinoids.
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l Glossary
AIDS — acquired immune deficiency syndrome.
Cannabinoids — substances found in the cannabis plant that act on specific receptors in 
the human brain and body; they are the main active ingredients in both the medicinal 
products derived from cannabis and cannabis preparations. The two most extensively 
studied cannabinoids are THC and CBD. Cannabinoids are also found in the human body 
(endocannabinoids), but those consumed for medical use may originate from the cannabis 
plant (plant-derived cannabinoids, also known as phytocannabinoids) or be synthesised in 
the laboratory (synthetic cannabinoids).
Cannabis magistral preparation — raw cannabis transformed by a pharmacist for 
consumption, in accordance with a specified medical prescription for an individual patient.
Cannabis preparations — in this report, items derived from the Cannabis sativa plant that 
do not have a marketing authorisation for medical use. These may include the raw 
cannabis, such as the flowering tops, compressed resin or hash; oils extracted from the 
plant; concentrated cannabis extracts; and other cannabis preparations, such as soft gels, 
tinctures or edibles.
CBD — cannabidiol; see cannabinoids.
CNCP — chronic non-cancer pain.
Dronabinol — synthetic THC; active ingredient of authorised medicinal products such as 
Marinol and Syndros. However, ‘dronabinol’ may sometimes be used to refer to plant-
derived THC.
EEA — European Economic Area.
EMA — European Medicines Agency.
EMCDDA — European Monitoring Centre for Drugs and Drug Addiction.
Endocannabinoids — see cannabinoids.
EU — European Union.
FDA — US Food and Drug Administration.
GP — general practitioner.
HIV — human immunodeficiency virus.
INCB — International Narcotics Control Board.
Nabilone — synthetic cannabinoid similar to THC; active ingredient of authorised 
medicinal products such as Cesamet and Canemes.
Nabiximols — plant-based cannabis extract containing approximately equal quantities of 
THC and CBD; active ingredient of authorised medicinal products such as Sativex.
NASEM — National Academies of Sciences, Engineering, and Medicine.
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OR — odds ratio.
Phytocannabinoids — see cannabinoids.
RCT — randomised controlled trial.
Standardised cannabis preparations — raw cannabis transformed by the manufacturer 
(e.g. into capsules) in larger batches, containing a constant composition of cannabinoids 
(examples of standardised cannabis preparations include preparations of cannabis 
flowers, such as Bedrocan; granulates, such as Bediol; and oil extracts, such as Tilray 
10:10 Balance).
Synthetic cannabinoids — cannabinoids synthesised in the laboratory.
THC — tetrahydrocannabinol; see cannabinoids.
UN — United Nations.
WHO — World Health Organization.
WHO-ECDD — WHO Expert Committee on Drug Dependence.
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